View

The Study

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

In simple terms

This study gave some people a medicine and others a fake pill, then watched who had heart problems. Because they were randomly assigned, we can guess the medicine probably caused the reduction in heart problems — but we’re not 100% sure because we don’t know if everyone was blinded.

68%

Analysis score

68/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting0
Methodology81
Publication100
Statistical77
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

People who had a stent but never had a heart attack were given a cholesterol-lowering drug or a sugar pill. After almost 5 years, those on the drug had fewer heart attacks and other heart problems.

Where does this study sit?

Systematic Reviews & Meta-analyses

Max 100

Randomized Trials

Max 90

Cohort Studies

Max 72

Case-Control

Max 58

Cross-Sectional

Max 44

Case Reports & Series

Max 30

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
68

68 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1Yes — cutting heart attacks in half and reducing deaths by a third is a big benefit for people who already had a stent but no prior heart attack.
  2. 2The drug lowered LDL cholesterol to 41.5 mg/dL (vs 107.0 on placebo).
  3. 3It cut heart attacks by half (3% vs 6%), reduced urgent heart procedures by 39%, and lowered heart-related deaths from 3.7% to 2.6%.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Circulation

Year

2026

Authors

B. Bergmark, E. Bohula, N. Marston, Jeong-Gun Park, J. Kuder, S. Murphy, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C Nicolau, O. Averkov, M. Charng, C. Ebenbichler, A. Erglis, I. Gouni-Berthold, G. Montalescot, S. J. Nicholls, A. Sigurdsson, Peter Sinnaeve, R. Šlapikas, K. Tsioufis, Subodh Verma, M. Viigimaa, Ajay K. Bhatia, Li Xin, E. Walsh, E. Ohman, Robert P. Giugliano, M. Sabatine

Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.